If you're struggling to find what you need, call our Support line on 7 days a week, 8am-8pm. HER2 human epidermal growth factor is a protein that can affect the growth of some breast cancer cells. If higher levels of it are found in a breast cancer, it is called HER2 positive breast cancer.
HER2 status also helps your doctor determine how aggressive the cancer is and treatment options. There are many differences between HER2 positive and HER2 negative breast cancers, from the biology of the tumors, to risk factors, aggressiveness, and much more. Understanding these differences is critical for anyone who has learned they have a positive HER2 status.
Some breast cancer cells have a higher than normal level of a protein called HER2 human epidermal growth factor receptor 2 on their surface, which stimulates them to grow. Around one in five invasive breast cancers breast cancer that has the potential to spread to other parts of the body are HER2 positive. All invasive breast cancers are tested for HER2 levels.
As previously reported, the strategy does not worsen two-year overall survival but significantly shortens progression-free survival. The phase II trial randomly allocated patients to trastuzumab plus pertuzumab alone versus trastuzumab plus pertuzumab combined with chemotherapy until progression. After progression, both groups received T-DM1 as second line therapy. Progression-free survival after first line therapy was 8.
HER2-positive breast cancer is a breast cancer that tests positive for a protein called human epidermal growth factor receptor 2 HER2which promotes the growth of cancer cells. In about 1 of every 5 breast cancers, the cancer cells have a gene mutation that makes an excess of the HER2 protein. HER2-positive breast cancers tend to be more aggressive than other types of breast cancer.
Genes contain the recipes for the various proteins a cell needs to stay healthy and function normally. Some genes and the proteins they make can influence how a breast cancer behaves and how it might respond to a specific treatment. Cancer cells from a tissue sample can be tested to see which genes are normal and abnormal.
By Alice Goodman December 10, Advertisement. Recent studies have more clearly defined the role of pertuzumab Perjeta and neratinib Nerlynx. A question currently on the table is the optimal duration of trastuzumab.
It is associated with a more aggressive disease, higher recurrence rate, and increased mortality. Trastuzumab is a HER2 receptor blocker that has become the standard of care for the treatment of HER2 positive breast cancer. The effectiveness of Trastuzumab has been well validated in research as well as in clinical practice.
When NCI-supported researchers discovered that the HER2 gene is important for breast cancer growth, this led to the development of the drug trastuzumab and other targeted treatments that have improved survival for women with HER2-positive breast cancer. For years, doctors and researchers have noted that not all cancers are alike. But for other patients, their tumors grow rapidly and spread like wildfire. In the early s, after the discovery that a mutated gene called HER2 could stimulate excessive cell growth and division, many scientists wondered if certain genes might make cancers grow and spread rapidly.